Moreover, SCLC cell lines have already been tested against seven of these drugs (CancerRxGene database40), namely dasatinib (targeting EPHA2), vorinostat (targeting HDAC1), imatinib, pazopanib, sorafenib, sunitinib and tivozanib (all targeting KIT). The gene discussed is EPHA2; the disease is small cell lung carcinoma.